Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
Rhea-AI Summary
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ALT declined 3.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association’s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
| Session Title: | Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1 |
| Session Date/Time: | Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT |
| Presentation Title: | Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight |
| Presenter: | John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune |
| Presentation Date/Time: | Saturday, June 21, 2025 at 5:45 PM CDT |
Details of the poster presentations are as follows:
| Title: | Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P) |
| Presenter: | Shaheen Tomah, M.D., Director, Clinical Development, Altimmune |
| Presentation Date/Time: | Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT |
| Title: | Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P) |
| Presenter: | Shaheen Tomah, M.D., Director, Clinical Development, Altimmune |
| Presentation Date/Time: | Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT |
| Title: | Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P) |
| Presenter: | John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune |
| Presentation Date/Time: | Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT |
These presentations will be accessible on the Events section of the Altimmune website.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide completed the MOMENTUM Phase 2 obesity trial in 2024 and is being studied in the ongoing IMPACT Phase 2b MASH trial with top line results expected in Q2 2025. IND applications in AUD and ALD have received FDA clearance with the Phase 2 trial in AUD having commenced in Q2 2025 and the ALD trial scheduled to commence in Q3 2025.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
What is Altimmune's pemvidutide and what conditions is it being developed for?
When and where will Altimmune (ALT) present their pemvidutide research?
What are the main topics of Altimmune's presentations at ADA 2025?
Who are the key presenters for Altimmune at the ADA Scientific Sessions 2025?
